PT-141 (Bremelanotida)
Melanocortin receptor agonist (MC4R)
Melanocortin agonist approved for hypoactive sexual desire.
Back to technical sheets- Class
- Melanocortin receptor agonist (MC4R)
- Also known as
- Approved as bremelanotide (e.g. Vyleesi®) for a specific indication
Mechanism of action
Agonist of central melanocortin receptors that modulates pathways involved in sexual desire, through a central (non-vascular) mechanism.
Evidence
Clinical evidence: FDA-approved for hypoactive sexual desire disorder in premenopausal women, with controlled trials.
Studied uses
- Hypoactive sexual desire disorder (premenopausal women)
Safety considerations
- Frequent nausea; transient blood-pressure increases
- Contraindicated in uncontrolled hypertension or cardiovascular disease
- Possible hyperpigmentation
Batch quality data
We publish these figures because they are the ones the program itself teaches you to ask for.
- Purity
- ≥ 98 % (HPLC)
- Net content
- 81 %
- Batch
- PT1-2601
- Presentation
- Polvo liofilizado en vial sellado
Net content is the fraction of the vial’s weight that is actually peptide, after discounting water, salts and excipients. It is the figure to calculate with, not the label weight.
Sample prices and batch data while the real ones are loaded.
Educational reference sheet. It is not a recommendation to use, a clinical indication or a protocol. Many of these compounds are marketed for research use only and are not approved for human use. Always cross-check with the primary literature and the regulation in your country.